Clinical Outcomes and Safety of Concurrent Chemoradiotherapy in EGFR-Mutant Unresectable Stage III NSCLC.

Takamori S, Shimokawa T, Osoegawa A, Abe M, Takumi Y, Sugawara S, Niho S, Goto Y, Okamoto H, Hotta K, Ozawa Y, Oizumi S, Yamamoto N, Mitsudomi T, Yamaguchi M

Open source

DOI
10.1016/j.jtocrr.2025.100897
Published
2026 Apr
Container
JTO clinical and research reports
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.jtocrr.2025.100897,
  title = {Clinical Outcomes and Safety of Concurrent Chemoradiotherapy in EGFR-Mutant Unresectable Stage III NSCLC.},
  author = {Takamori S and Shimokawa T and Osoegawa A and Abe M and Takumi Y and Sugawara S and Niho S and Goto Y and Okamoto H and Hotta K and Ozawa Y and Oizumi S and Yamamoto N and Mitsudomi T and Yamaguchi M},
  year = {2026},
  journal = {JTO clinical and research reports},
  doi = {10.1016/j.jtocrr.2025.100897},
  url = {https://doi.org/10.1016/j.jtocrr.2025.100897}
}

RIS

TY  - JOUR
TI  - Clinical Outcomes and Safety of Concurrent Chemoradiotherapy in EGFR-Mutant Unresectable Stage III NSCLC.
AU  - Takamori S
AU  - Shimokawa T
AU  - Osoegawa A
AU  - Abe M
AU  - Takumi Y
AU  - Sugawara S
AU  - Niho S
AU  - Goto Y
AU  - Okamoto H
AU  - Hotta K
AU  - Ozawa Y
AU  - Oizumi S
AU  - Yamamoto N
AU  - Mitsudomi T
AU  - Yamaguchi M
PY  - 2026
JO  - JTO clinical and research reports
DO  - 10.1016/j.jtocrr.2025.100897
UR  - https://doi.org/10.1016/j.jtocrr.2025.100897
ER  -

APA

S, T., T, S., A, O., M, A., Y, T., S, S., S, N., Y, G., H, O., K, H., Y, O., S, O., N, Y., T, M., & M, Y. (2026). Clinical Outcomes and Safety of Concurrent Chemoradiotherapy in EGFR-Mutant Unresectable Stage III NSCLC.. JTO clinical and research reports. https://doi.org/10.1016/j.jtocrr.2025.100897

Source records